Accessibility Menu
 
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

(NASDAQ) VRTX

Current Price$438.29
Market Cap$111.45B
Since IPO (1991)+9,649%
5 Year+106%
1 Year-9%
1 Month-8%

Vertex Pharmaceuticals Financials at a Glance

Market Cap

$111.45B

Revenue (TTM)

$12.04B

Net Income (TTM)

$3.95B

EPS (TTM)

$15.33

P/E Ratio

28.61

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Price

$438.29

Volume

54,487

Open

$443.01

Previous Close

$438.29

Daily Range

$436.70 - $449.17

52-Week Range

$362.50 - $510.77

VRTX: Motley Fool Moneyball Superscore

82

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vertex Pharmaceuticals

Industry

Biotechnology

Employees

6,400

CEO

Reshma Kewalramani, MD

Headquarters

Boston, MA 02210, US

VRTX Financials

Key Financial Metrics (TTM)

Gross Margin

86%

Operating Margin

35%

Net Income Margin

33%

Return on Equity

23%

Return on Capital

19%

Return on Assets

15%

Earnings Yield

3.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$111.45B

Shares Outstanding

254.03M

Volume

54.49K

Short Interest

0.00%

Avg. Volume

1.52M

Financials (TTM)

Gross Profit

$10.27B

Operating Income

$4.76B

EBITDA

$4.97B

Operating Cash Flow

$3.63B

Capital Expenditure

$437.60M

Free Cash Flow

$3.19B

Cash & ST Invst.

$6.61B

Total Debt

$3.88B

Vertex Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$3.23B

+10.8%

Gross Profit

$2.76B

+10.9%

Gross Margin

85.56%

N/A

Market Cap

$111.45B

N/A

Market Cap/Employee

$18.27M

N/A

Employees

6,100

N/A

Net Income

$1.19B

+30.5%

EBITDA

$1.35B

+14.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$2.73B

-37.5%

Accounts Receivable

$2.05B

+27.6%

Inventory

$1.69B

+39.9%

Long Term Debt

$3.80B

+129.3%

Short Term Debt

$82.80M

-10.3%

Return on Assets

15.12%

N/A

Return on Invested Capital

19.15%

N/A

Free Cash Flow

$348.60M

-29.1%

Operating Cash Flow

$498.00M

-14.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDTMedtronic plc
$86.63+0.66%
MCKMcKesson Corporation
$884.28+1.37%
GSKGSK plc
$56.69+1.25%
SNYSanofi
$47.89+0.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
INTCIntel
$50.38+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%

Questions About VRTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.